

Journal Club Mai 2023

Termin: 04.05.2023
Klinischer Teil: Kein klinischer Vortrag
DOI:
Referent/in:

Wissenschaftlicher Teil: The addition of arginine deiminase potentiates Mithramycin A-induced cell death in patient-derived glioblastoma cells via ATF4 and cytochrome Cudy
DOI: <https://doi.org/10.1186/s12935-023-02873-2>
Referent/in: Charlotte Linke

Termin: 11.05.2023
Klinischer Teil: Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study
DOI: [https://doi.org/10.1016/S2352-3026\(22\)00386-6](https://doi.org/10.1016/S2352-3026(22)00386-6)
Referent/in: Rebekka Karrengarn

Wissenschaftlicher Teil: Non-viral precision T cell receptor replacement for personalized cell therapy
DOI: <https://doi.org/10.1038/s41586-022-05531-1>
Referent/in: Robby Engelmann

Termin: 18.05.2023 (Feiertag)
Klinischer Teil:
DOI:
Referent/in:

Wissenschaftlicher Teil:
DOI:
Referent/in:

Termin: 25.05.2023
Klinischer Teil: Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up
DOI: <https://doi.org/10.1200/JCO.22.00842>
Referent/in: Dr. med. Christian Schmidt

Wissenschaftlicher Teil: First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With
DOI: <https://doi.org/10.1200/JCO.21.02752>
Referent/in: Jana Scheffler